Leveraging the complementary advantages of digital PCR (dPCR) and quantitative PCR (qPCR), Aperbio has developed a suite of validated molecular diagnostic solutions for comprehensive cancer management - from early detection and auxiliary diagnosis to companion diagnostics - with demonstrated utility in major cancer types such as lung, colorectal and hepatobiliary malignancies, etc.